Search results

In development Reference number: GID-TA11454 Expected publication date:  23 July 2026

Result type

Technology appraisal guidance

Status

In development

This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.

Result type

Clinical guideline

Last updated

22 September 2020

Evidence-based recommendations on percutaneous cementoplasty for palliative treatment of bony malignancies. This involves injecting a special cement into the bone in order to stabilise it, reduce pain, or both.

Result type

HealthTech guidance

Published

28 June 2006

Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.

Result type

Technology appraisal guidance

Published

1 July 2020

Evidence-based recommendations on laparoscopic hysterectomy (including laparoscopic total hysterectomy and laparoscopically assisted vaginal hysterectomy) for endometrial cancer. This involves removing the uterus through several small cuts in the abdomen (keyhole surgery), with the aid of an internal telescope and camera.

Result type

HealthTech guidance

Published

22 September 2010

Evidence-based recommendations on cabozantinib (Cabometyx) for advanced hepatocellular carcinoma in adults who have had sorafenib.

Result type

Technology appraisal guidance

Published

14 December 2022

Evidence-based recommendations on low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. This involves applying low-energy lasers to the affected tissue.

Result type

HealthTech guidance

Published

23 May 2018

Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning in people having external beam radiotherapy.

Result type

HealthTech guidance

Published

27 September 2023

Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin) for treating advanced or unresectable hepatocellular carcinoma in adults who have not had previous systemic treatment.

Result type

Technology appraisal guidance

Published

16 December 2020

Evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.

Result type

Technology appraisal guidance

Published

11 September 2024

This guidance has been updated and replaced by NICE guideline NG47.

Result type

Withdrawn guideline

Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.

Result type

Technology appraisal guidance

Published

15 November 2017

Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults after 2 or more treatments.

Result type

Technology appraisal guidance

Published

14 December 2022

Evidence-based recommendations on high dose rate brachytherapy for carinoma of the cervix. This involves giving radiation at a high dose rate to the cervix (reducing the timeframe compared with low or medium dose rates) to treat the cancer.

Result type

HealthTech guidance

Published

22 March 2006

This guideline covers diagnosing and managing pancreatic cancer in adults aged 18 and over. It aims to improve care by ensuring quicker and more accurate diagnosis, and by specifying the most effective treatments for people depending on how advanced their cancer is.

Result type

NICE guideline

Published

7 February 2018